Please login to the form below

Not currently logged in
Email:
Password:

Tony de Fougerolles joins Evox Therapeutics as CEO

He succeeds Dr Per Lundin who stays at the firm as COO

TonyOxford, UK-based Evox Therapeutics has appointed its new chief executive officer in the form of Tony de Fougerolles.

He succeeds Dr Per Lundin who will continue in his role as chief operating officer of the biotherapeutics company, overseeing operational aspects of its business as well as advancing and expanding the company’s intellectual property estate.

Dr Lundin said: “After a thorough selection process, I am incredibly pleased that Tony is joining the team as we continue to develop Evox into the world’s leading exosome therapeutics company.

“Tony has an outstanding track record in progressing products through the pipeline and a strong scientific understanding.

“He has also been integral to his previous companies’ deal-making success and we are exciting for him to bring such extensive experience to Evox.”

Fougerolles joins the company from Ablynx, where he held the role of chief scientific officer for four years expanding its pipeline and forming new partnerships.

Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.

He said: “Having worked as a chief scientific officer for seven years, I appreciate the fine balance between developing new drug platforms, advancing a therapeutic pipeline, and building the business.

“I believe we can progress through the clinic an entirely novel class of biotherapeutics and I look forward to working with Per and the rest of the board to develop therapies with a potentially transformative impact on the lives of patients suffering from severe illnesses.”

22nd November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics